Adeno-associated virus (AAV) vectors are capable of delivering a therapeutic gene to the mouse brain that can result in long-term and widespread protein production. However, the human infant brain is more than 1000 times larger than the mouse brain, which will make the treatment of global neurometabolic disorders in children more difficult. In this study, we evaluated the ability of three AAV serotypes (1,2, and 5) to transduce cells in the cat brain as a model of a large mammalian brain. The human lysosomal enzyme bglucuronidase (GUSB) was used as a reporter gene, because it can be distinguished from feline GUSB by heat stability. The vectors were injected into the cerebral cortex, caudate nucleus, thalamus, corona radiata, internal capsule, and centrum semiovale of 8-week-old cats. The brains were evaluated for gene expression using in situ hybridization and enzyme histochemistry 10 weeks after surgery. The AAV2 vector was capable of transducing cells in the gray matter, while the AAV1 vector resulted in greater transduction of the gray matter than AAV2 as well as transduction of the white matter. AAV5 did not result in detectable transduction in the cat brain.
Introduction
A large number of single-gene disorders affect the central nervous system (CNS), many of which result from functional deficiencies of specific enzymes in metabolic pathways. 1 Somatic gene transfer has the potential to correct permanently the metabolic deficiency by transferring a normal copy of the defective gene into a patient's own cells. Gene transfer to neurons and glia of the brain requires circumvention of the blood-brain barrier, which is commonly accomplished by delivering vectors directly into the brain. 2 A major problem in treating the brain in inherited metabolic disorders is delivering the gene or its protein product globally. Although this can be achieved under certain circumstances in the mouse brain, it is a much more difficult problem in a large brain. [3] [4] [5] [6] [7] [8] [9] The brain of a child in the first year of life, when disease diagnosis is most likely and treatment is expected to be most effective, is 1000-2000 times larger than the mouse brain. To provide a foundation for initiating human gene therapy trials, gene transfer to large regions of the brain will need to be demonstrated in a large animal model.
We evaluated recombinant adeno-associated virus (rAAV) vector-mediated transduction of the cat brain following direct intracerebral inoculation. The cat was chosen for study because: (1) many naturally occurring inherited metabolic disorders affect the cat brain; [10] [11] [12] (2) the feline nervous system has been well-characterized both anatomically and physiologically; 13, 14 ( 3) the cat brain is approximately 100 times larger than the mouse brain, and (4) the physical organization of the cat brain is more similar to the human brain than is the rodent brain.
Recombinant AAV vectors are excellent for gene transfer to the CNS. They are nonpathogenic, can be produced in high titers, can infect the nondividing cells of the brain, and can result in long-term gene expression in the murine brain. 15 Nine AAV serotypes have been identified, which differ in their capsids proteins. 15, 16 Comparison of the ability of three different AAV serotypes, AAV2, 4, and 5, to transduce the mouse brain revealed that while intrastriatal injection of either AAV2 or AAV5 led to transgene-positive parenchymal cells, AAV5 resulted in the greatest number of transgenepositive cells. 17 We compared the ability of three rAAV serotypes, AAV1, 2, and 5, to achieve gene transfer in the normal cat brain. b-glucuronidase (GUSB) was used as a marker gene due to the ability to monitor enzyme expression using histochemical staining and mRNA expression using in situ hybridization on frozen brain sections.
Results
A plasmid containing AAV2 inverted terminal repeats (ITRs) flanking a transcription unit (HbH) containing the human GUSB cDNA under the control of the human GUSB promoter was cross-packaged into AAV1, AAV2, and AAV5 capsids, resulting in three viral vectors each containing the same recombinant genome. The titer of each of the three viral vectors, designated AAV2/1, AAV2/2, and AAV2/5, was 4.9 Â 10 12 , 4.5 Â 10 12 , and 4.5 Â 10 12 genomic equivalents (GE)/ml, respectively. Eight-week-old cats (n¼5) were injected intracerebrally with AAV vectors (Figure 1 ). Cats were injected with a total of 50 ml (B12 ml per needle track) of either the AAV2/1, AAV2/2, or AAV2/5 vector. Each injected hemisphere received only one AAV serotype and no cats received the same serotype in both cerebral hemispheres. All cats recovered and were eating well within 12 h of surgery. No cats showed any abnormal clinical signs during the 10-week period of study.
Expression of GUSB activity in the brain
The five injected cats were euthanized 10 weeks after surgery (18 weeks of age) along with two uninjected, age-matched control cats. The brains were perfused, removed, formalin-fixed, frozen, sectioned transversely, and examined for GUSB activity using a histochemical stain. 18 Low levels of endogenous intracellular feline GUSB activity were undetectable with this method, although the white matter stained diffusely a pale pink (not shown). This faint staining was removed by heating slides to 651C prior to staining to inactivate native feline GUSB in the same manner used to inactivate murine GUSB compared to human GUSB, which is heat stabile. 8, 19 A mild to moderate infiltration of inflammatory cells was variably seen along the needle track in all injected cats. Injection of AAV2/1 and AAV2/2 resulted in detectable GUSB activity, as assessed by histochemical staining, along the needle track in the gray matter (cortex of the frontal lobe, the caudate nucleus, and the thalamus) (Figure 2a, b, d , e, g, h). Cats injected with AAV2/5 ( Figure 2c , f, i) and uninjected control cats (Figure 2j ) showed no histochemical evidence of GUSB activity in the gray matter. Comparison of AAV2/1 versus AAV2/2 in the gray matter showed qualitatively stronger histochemical staining and positively stained cells at farther distances from the needle track with AAV2/1. AAV2/2 resulted in most cells staining positive for GUSB activity immediately adjacent to the needle track (Figure 2b , e, h). In contrast, AAV2/1 resulted in many GUSB-positive cells as far as 2 mm from either side of the needle track (Figure 2a, d, g ). The histochemical staining in AAV2/1-injected cats was the strongest in the caudate nucleus ( Figure 2d ). Similar patterns of GUSB activity were found in all three cats injected with AAV2/1 and AAV2/2.
The maximum rostro-caudal and medio-lateral distances from the needle track in which GUSB-positive cells were present in the gray matter was measured in cats injected with the same vector, averaged, and compared between AAV2/1-and AAV2/2-injected cats ( Table 1 ). The diameter of the region of brain surrounding the needle track that contained GUSB-positive cells was significantly greater (Po0.05) in AAV2/1-injected cats than in AAV2/2-injected cats in the caudate nucleus (Table 1) . A second quantitative method was also used to compare GUSB staining between cats injected with different vectors. On the brain section containing the needle track, the area of GUSB-positive brain was calculated and compared between AAV2/1 and AAV2/ 2 ( Figure 3 ; Table 2 ). AAV2/1 resulted in a significantly greater area of GUSB-positive cells in the caudate nucleus than did AAV2/2.
In contrast to the gray matter, only AAV2/1 produced significant GUSB activity in the white matter (corona radiata of the frontal lobe, the centrum semiovale, corpus callosum, and the internal capsule) (Figure 4a, d, h ). GUSB-positive cells in AAV2/1-injected brains were found up to 5 mm from the needle track. In all cases, GUSB-positive cells were distributed along the white matter tracts and the number of positive cells diminished at increasing distances from the needle track (Figure 4a , d, h). Injection of AAV2/2 only resulted in rare GUSB-positive cells in the centrum semiovale and internal capsule (Figure 4e,i) . Interestingly, the gray matter both dorsal and ventral to the white matter tract often showed many GUSB-positive cells after AAV2/2 injection (4i).
Finally, in AAV2/1-injected cats, GUSB-positive cells could be found in a continuous line in the injection tracks extending from the dorsal cortex, through the corona radiata, the deep gray matter (caudate nucleus or thalamus), the internal capsule, to the ventral cortex (a dorso-ventral distance of 25 mm).
In situ hybridization
Since GUSB is a secreted enzyme that is endocytosed by neighboring untransduced cells, 20, 21 we determined whether histochemically positive cells were cross-corrected or whether they expressed GUSB mRNA. In all 
Discussion
Nine AAV serotypes have been identified. 16, [22] [23] [24] [25] [26] Specific AAV serotypes differ in the composition of their capsid proteins and in their ability to transduce lung, muscle, and brain. 27 Cross-packaging of the AAV2 vector genome into other AAV serotypes demonstrated that the amino acids of the capsids are responsible for some of the differences in cellular tropism. 16, 17, 26, 28, 29 The different capsids likely result in differences in binding to cellular receptors as evidenced by the ability of AAV1, AAV2, and AAV3 to bind to heparan sulfate, while AAV4 and 5 do not. 25, 27 The receptors for AAV2 and AAV5, heparan sulfate proteoglycans and 2,3-linked sialic acid, respectively, have been determined. 27, 30 The cellular receptor for AAV1 has not been identified.
In the mouse brain, gene transfer using three recombinant AAV serotypes, AAV2, AAV4, and AAV5, with a variety of promoters and genes has been performed. [3] [4] [5] 7, 8, 17, [31] [32] [33] [34] All but two studies examined AAV2-mediated transduction alone. 17, 35 A direct comparison of intracerebral injection in adult mice of AAV2, AAV4, and AAV5, each containing the Rous sarcoma virus (RSV) long-terminal repeat promoter and the lacZ gene, found that AAV2 and AAV5 could transduce cells in the striatum, but that AAV5 resulted in greater numbers of positive cells at longer time points, whereas, AAV4 resulted in almost exclusive transduction of ependymal cells. 17 In this study, the AAV2 and AAV4 vectors each contained the same vector genome and differences in transduction patterns could only be explained by differences in the composition of the viral capsids. In contrast, the AAV5 vector used the AAV5 inverted terminal repeats (ITRs), which may have contributed to the differences in gene expression. 17 Three other species (rat, gerbil, and monkey) have been examined for AAV vector transduction in the brain. However, since a variety of promoters, transgenes, ITRs, and brain regions have been used, a direct comparison between species is not possible. [36] [37] [38] [39] [40] [41] A comparison of AAV2 and AAV5 injection into the rat striatum indicated that AAV5 transduction was less predictable in the direction of spread and in the volume of transduction than AAV2. 41 There have been no studies examining the ability of AAV1 to transduce the brain in the adult of any species. Figure 4 GUSB activity in the white matter. AAV2/1 transferred GUSB activity to the corona radiata, centrum semiovale, corpus callosum, and internal capsule (a,d,h). In contrast, AAV2/2-injected cat brain showed rare GUSB-positive cells within the white matter (arrowheads in e and i) and evidence of transduction of gray matter surrounding the white matter (arrows in i). Neither the AAV2/5-injected cat brain (c,f,j) nor the uninjected control cat brain (g) showed any evidence of GUSB activity. (lettered panels a-f¼ Â 25 magnification; lettered panels h-j¼ Â 100 magnification; insets¼ Â 400 magnification; size bar in c and j¼0.5 mm).
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For studies in the cat brain, each of the three vectors contained the same genome with the only difference being the composition of the capsids. Of the three serotypes tested, only AAV2/1 and AAV2/2 were capable of transducing the cat brain as determined by in situ hybridization. Low levels of in situ hybridization positive staining were seen with the sense riboprobe. We have also observed this in mice where it has been shown that episomal forms of vector DNA persist in brain tissue, therefore, small amounts of sense riboprobe may have hybridized to the nontranscribed strand of the episomal DNA. 3, 42 No evidence of hybridization was seen in regions of uninjected brain using either the sense or antisense riboprobe.
In all cats, positive histochemical staining colocalized with positive in situ hybridization staining. This indicated the presence of vector genome in the majority of histochemically positive cells and only local spread of enzyme by diffusion between cells. However, the distal spread of enzyme activity away from transduced cells may be below histochemical detection. 21 No evidence of retro-or anterograde transport in the cat brain was found with any of the three serotypes used. Although axonal transport of a lysosomal enzyme has been reported in the mouse, 42 there are several possible explanations for this apparent difference. First, the regions of the brain in which transport was examined in the mouse, the intrahippocampal and septohippocampal pathways, were not tested in the cat so a direct comparison is not possible. Second, substantial evidence of axonal transport in the mouse brain was not identified until 12 weeks post-transduction in the mouse. Since the cat brain is significantly larger than the mouse brain, with correspondingly longer axons, it is possible that evidence of axonal transport would not be found until much later than 10 weeks after viral injection. Third, low levels of enzyme may have undergone axonal transport, but were below the limits of histochemical detection. Finally, although possible, it seems unlikely that differences in axonal transport of lysosomal enzymes would exist between species.
Comparison of AAV2/1 to AAV2/2 showed that while both were capable of transducing cortical and deep gray matter of the brain, AAV2/1 transduced a larger region of brain and at farther distances from the injection track, particularly in the caudate nucleus. In contrast, only AAV2/1 was capable of transduction of the white matter. These data suggest that while the receptors for both AAV1 and AAV2 are present within the gray matter of the cat brain, only AAV1 receptors are found in the white matter. In the mouse brain, AAV2 transduces primarily neurons. 3, 8, 17, 42, 43 In the cat brain, the fact that AAV2/2 transduces only the gray matter, in addition to the neuronal-like shape of the transduced cells (Figure 2) , suggests that neuronal transduction is also occurring. In the cat, AAV2/1 transduced both gray and white matter in the cat brain, suggesting that AAV2/1 is capable of also 17, 35 In the cat experiments, the expression cassette was flanked by AAV2 ITRs and a eucaryotic promoter was used. Since the promoter, cDNA, ITR, and viral titer may all effect transduction, 15 it is not known whether differences in transduction between the mouse and cat were due to species or vector differences. We are currently examining the transduction pattern of different AAV serotypes in the mouse brain. The same viral preparation of AAV2/5 resulted in transduction of the choroid plexus and ependymal cells of the mouse brain (MAP and JHW, unpublished). It will be important to compare transduction patterns among species and it must be noted that the transduction pattern seen in the cat and mouse may differ in primates.
There is a wealth of basic data on the cat brain due to the decades-long use of cats in neurobiological studies. 13, 14 There are also many single-gene disorders in the cat that affect the CNS, making the cat a useful model for diseases that affect human patients. [10] [11] [12] Our studies show that AAV2/1 was the most efficient at transferring GUSB activity in major gray and white matter structures of the cat brain. Indeed, AAV2/1 transduced all regions along the dorso-ventral needle track resulting in a vertical 'cylinder' of transduction. Using an averaged 1.5 mm radius of transduction from the injection track results in a calculated 7.1 mm 2 dorsal-plane crosssectional area of transduction around each needle track.
The data from these experiments are being used to design treatment strategies for diffuse brain disease, such as lysosomal storage diseases, which occur naturally in the cat. One of these diseases, mucopolysaccharidosis type VII (MPSVII), is caused by inherited GUSB deficiency that results in the lysosomal storage of substrate. In MPS VII and other lysosomal storage diseases, correction of mutant cells by direct gene transfer results in correction of storage in the transduced cell as well as in neighboring untransduced cells. Correction of storage in neighboring cells occurs by endocytosis of secreted lysosomal enzymes from transduced cells. 20, 21 Our studies in the MPSVII mouse have shown that the secreted GUSB can resolve lysosomal storage lesion in the brain at least 2 mm away from GUSB positively stained cells. 3, 21 This shows that although enzyme was present in neighboring untransduced cells, it was below the level of histochemical detection. Using AAV2/1 in the cat brain, if GUSB were present at therapeutic levels 2 mm beyond histochemically positive areas, this would result in an approximately 38 mm 2 dorsal-plane cross-sectional area of correction. Thus, the whole cat brain, which at its widest dorsal-plane width is approximately 1250 mm 
Methods rAAV vector production
The detailed construction of the rAAV genome used in this study was previously reported. 8 The genome contained AAV2 ITRs flanking a 2.6 kb transcription unit (HbH) containing the human 2.2 kb GUSB cDNA under the control of the 0.4 kb human GUSB promoter, a 0.4 kb SV40 splice donor-acceptor and poly A sequences, and a 1.4 kb stuffer sequence that resulted in a genome size of 4.7 kb. The plasmid was cross-packaged, by the Institute of Human Gene Therapy at the University of Pennsylvania, into AAV1, AAV2, and AAV5 capsids resulting in three viral vectors each containing the same AAV2-HbH genome. 26, 44 The titer of each of the three viral vectors, designated AAV2/1, AAV2/2, and AAV2/ 5, was 4. 
Animals
Seven normal cats were raised in the animal colony of the School of Veterinary Medicine of the University of Pennsylvania, under NIH and USDA guidelines for the care and use of animals in research. The animals were housed at 211C with ad libitum food and water, 12-h light cycles, with 12-15 air changes per hour. At 8 weeks of age, five cats were anesthetized with intravenous propofol (up to 6 mg/kg; Abbott Laboratories, Chicago, IL, USA), endotracheally intubated, maintained under anesthesia with isoflurane (IsoVet; Schering-Plough, Omaha, NE, USA), and placed in a nonferrous stereotaxic head holder designed by the investigators. The brain was imaged either by computerized tomography or magnetic resonance imaging to determine the coordinates of the brain structures of interest. These included the cortex of the frontal lobe, the head of the caudate nucleus, the thalamus, the corona radiata of the frontal lobe, the centrum semiovale, and the internal capsule. Following imaging, each cat was prepared for surgery. A midline incision was made over the dorsum of the calvaria and four holes, 1 mm in diameter, were drilled in each side of the calvaria over the brain regions of interest (Figure 1) . A 25 ml Hamilton syringe with a 26 G needle was used to administer each rAAV vector. The needle was placed into each drill hole and lowered to the base of the brain, 2 ml of vector was injected and allowed for vector diffusion for 2 min. The needle was then withdrawn vertically at 0.5 cm distances and the injection procedure repeated until the needle was no longer in the brain. A total of 50 ml of vector was administered per cerebral hemisphere of each cat. Each cerebral hemisphere received only one of the rAAV serotypes ( Table 1 ). The two additional cats served as control cats for in situ hybridization and histochemistry and did not have surgery performed.
Preparation of brain tissue
The five injected cats were killed at 18 weeks of age, 10 weeks after surgery, using an intravenous overdose of AAV in the cat brain CH Vite et al barbiturate (Fatal-Plus; Vortech Pharmaceuticals, Dearborn, IL, USA) in accordance with the American Veterinary Medical Association guidelines. Additionally, two uninjected cats were killed at 18 weeks of age. Immediately prior to killing 0.5 cc of heparin (1000 U/ ml) was administered intravenously. Following killing, intracardiac perfusion with 250 ml of 0.9% cold saline was followed by 750 ml of neutral buffered 10% formalin containing 0.75 g chloral hydrate. Brains were removed, sectioned transversely, fixed in 10% formalin/chloral hydrate for an additional 24 h and then transferred to 30% sucrose-phosphate-buffered saline at 41C until the sections no longer floated. Brain sections were then placed in OCT media (Tissue-Tek; Sakura Finetechnical Co, Tokyo, Japan), frozen, and cryosectioned transversely at a thickness of 20 mm. Tissue sections were placed on slides for staining and stored at À201C until staining was performed.
Enzyme histochemistry
GUSB activity was assessed in frozen tissue by staining with a naphthol-AS-BI-b-D-glucuronide substrate and a pararosaniline dye that stains tissue red when GUSB activity is present. 18 Low levels of endogenous intracellular feline GUSB activity were undetectable with this method, although the white matter stained diffusely a pale pink. This faint staining was removed by heating slides to 651C prior to staining to inactivate native feline GUSB in the same manner used to inactivate murine GUSB. 8, 19 The human GUSB was not heat labile resulting in positive histochemical staining in the brains of transduced cats.
The distance from the needle track and the area in which red, histochemically positive cells were present was measured using a microscope and a software program (ImagePro Plus; Media Cybernetics LP, Silver Springs, MD, USA). 45 Several brain sections were stained for GUSB activity and to locate hemosiderin that was used to identify the injection site. When hemosiderin was identified, the rostro-caudal distance of GUSB-positive cells was measured from this site by staining sections every 100 mm until the limit of GUSB-positive cells was reached. The medio-lateral limit was measured in each brain at the level of the injection track; measurements were made on two slides per each injection track. Area measurements were made on the histologic section containing the needle track, as evidenced by the presence of a visible linear line of hemosiderin resulting from the needle insertion. Area measurements were made on two slides per each injection track. The area in which GUSBpositive cells were present was measured by capturing digital bright field images, subtracting the green channel from the red channel and measuring the area of red staining on each slide. Subtraction of the green channel was performed to accentuate the red-stained area, because in unstained regions the intensities of the green and red images are similar but in stained regions there is an increased absorption of green light passing through the stain.
In situ hybridization
Nonradioactive in situ hybridization was performed on frozen tissue sections to detect hGUSB mRNA. A 1590 bp segment of the hGUSB cDNA was cloned into the Bluescript (Stratagene, La Jolla, CA, USA) plasmid. The plasmid was linearized to generate antisense and sense templates for runoff transcription from the cis-acting viral promoters. Digoxigenin-labeled (Roche, Indianapolis, IN, USA) antisense and sense cRNA probes were generated and the probe length was verified on a formaldehyde gel. The in situ hybridization protocol and colorometric staining using an alkaline phosphatasemediated BCIP/NBT reaction has been previously described. 8, 46 Sections from both in situ hybridization and enzyme histochemistry reactions were mounted on 100% glycerol and photographed using a light microscope (Carl Zeiss Axioplan, Germany).
Statistics
Mean and standard deviation were used for comparison of all data. The unpaired t-test was used to compare distance from the needle track and area containing GUSB-positive cells between AAV2/1 and AAV2/2. Significance was determined when Po0.05.
